Philip Morris International Inc. (PM) Earnings Call Transcript & Summary
April 20, 2023
Earnings Call Speaker Segments
James Bushnell
executiveGood day, everyone, and thanks for being here. We released a press release earlier today that has all the specifics about how we performed in the first quarter of 2023. That release can be found at pmi.com. You'll find a glossary of terms — this includes what we mean by smoke-free products — plus adjustments, other calculations, and reconciliations to the most directly comparable U.S. GAAP measures for the non-GAAP financial measures referenced in this presentation, along with additional net revenue data, in the exhibit to the Form 8-K we published this morning and on our Investor Relations website. When growth rates are shown on an organic basis, they reflect currency neutral adjusted results that leave out acquisitions and disposals. So with that in mind, any figures and comparisons on an organic basis do not include Swedish Match prior to November 11, 2023. In today's remarks, there are forward-looking statements and projections of future results. Please turn your attention to the Forward-Looking and Cautionary Statements disclosure in today's presentation and press release, which reviews the various factors that could cause actual results to differ materially from projections or forward-looking statements. At this point, it's my pleasure to bring in Emmanuel Babeau, Chief Financial Officer. Emmanuel, the floor is yours.
Emmanuel Babeau
executiveThanks, James, and hello everyone. It's a pleasure to share that our first-quarter results came in above what we had anticipated, driven by solid underlying momentum from IQOS, ZYN, and our combustible segment. During our full-year earnings call in February, we noted that we anticipated this quarter would be the softest of the year, given a mix of temporary factors weighing on both our top and bottom lines. Against that backdrop, our business turned in strong results, and we're looking ahead with confidence to the rest of the year. Smoke-free net revenues accounted for nearly 35% of total PMI, even with adverse timing factors affecting HTU shipments, and a growing number of markets are now surpassing the 50% threshold. IQOS keeps generating robust share and user gains across its geographies, in both the blade version and ILUMA. In markets where it has launched, ILUMA's strong traction among both current IQOS users and legal-age smokers is fueling growth, which shows how dynamic and important our continued innovation is. ILUMA's momentum is particularly striking in Japan, the first launch market, where share gains have picked up pace in recent quarters. On combustibles, faster pricing actions across a variety of markets helped produce solid organic net revenue growth. Swedish Match turned in impressive results, highlighted by ZYN's 47% U.S. shipment volume growth versus the first quarter of 2022. We had a promising beginning to the year, and we're in a good position to achieve strong results in 2023, with great growth on both the top and bottom lines for the remainder of the year. Turning to the main numbers: organic net revenues for Q1 rose a solid 3.2%, compared with a very robust prior-year quarter that delivered 9% organic growth. That performance shows IQOS's ongoing momentum and an acceleration in pricing, although it was partially counterbalanced by anticipated HTU inventory shifts, which I'll come back to; this organic number does not include Swedish Match's outstanding 14% top-line growth in ex-currency terms, which was driven by ZYN. Our total reported currency-neutral net revenues increased 9.6%, and combined pro forma adjusted net revenues were up roughly 4%, again excluding currency. On a per-unit basis, our organic net revenue rose 4.4%. Combustible pricing was strong at 7.4%, though that was partly offset by HTU dynamics over in Japan and Germany, which I'll get into shortly. For Q1, adjusted diluted EPS came in at $1.38, which is comfortably ahead of what we'd previously expected. That's driven by strong underlying delivery from our existing operations, excellent Swedish Match performance, and favorable phasing on interest costs. Compared with a prior-year quarter that was a record high, and given a number of one-off or accentuated margin headwinds from inflation, supply chain inefficiencies, and timing factors as we flagged previously, our adjusted diluted EPS was down 4.4%. Let me now go through how Q1 net revenues came together. Our total adjusted net revenue was up 4.6%, even though organic shipment volume fell 1.1%. That figure doesn't include Swedish Match, whose smoke-free volumes climbed a strong 10%, which brought meaningful accretion to our overall growth profile. Turning to pricing for combustibles and HTUs—excluding Germany and Japan HTUs—that contributed 5.3 points of growth, and it reflects positive HTU pricing in a number of markets. Working partly in the opposite direction was a 1.3 point negative HTU impact from Germany and Japan. Of those two markets, Germany was the larger one, and that's because a full quarter of the 2022 excise tax hike was in play, with a court decision on that increase still pending sometime later this year. In Japan, our top line also took a hit from the October 2022 excise tax increase along with the shift over to ILUMA, and we figure part of that drag will taper off during the back half. As HTUs make up a growing share of what we sell, carrying a higher net revenue per unit, that trend continues to lift our results, though the benefit was capped by softer shipments in Europe this quarter, which came from how wholesalers and distributors moved their inventory. This additionally explained why a discrepancy existed between the expansion in our organic smoke-free net revenue and the increase in HTU shipment volumes. We anticipate that beneficial shift in product mix will pick up speed, since throughout the year both organic smoke-free net revenue growth and HTU shipment growth should move into closer alignment with offtake patterns, just as occurred during 2022. HTUs delivering a favorable mix effect, along with total volume expansion and price increases, serve as strong forces behind our transformation and growth. The first quarter, as anticipated, faced the steepest margin pressures at both the gross margin and adjusted operating income lines. A 0.6 percentage point reduction in gross margin resulted from the combined effect of COGS inflation, pricing, volume, mix, and productivity savings. As the year moves forward, we anticipate that favorable pricing, productivity gains, and a beneficial mix within the HTU category will more and more offset inflation, and eventually surpass it. An additional 0.6 percentage point hit came from supply chain interruptions along with the faster shift of both consumers and our operations toward ILUMA. We expect these factors to diminish as ILUMA rollouts continue and we achieve greater supply chain efficiency, such as resuming ocean freight. Furthermore, gross margin for the quarter was reduced by 1.8 percentage points because of how specific costs were timed and the geographic distribution of inventory flows, particularly for HTUs in Europe. Even with those remarkable dynamics in the first quarter, our projection for the heat-not-burn segment's effect on margins across the whole of 2023 remains positive, once shifts in inventory and elements tied to ILUMA fade away. So, as we laid out earlier, gross profit and OI margins should climb steadily, with the bulk of that gain landing in H2, when pressures ease and the core forces behind our transformation pick up speed. SG&A costs came in at roughly 26% of adjusted net revenues during Q1 — close to the same proportion seen for all of 2022 — yet, just as anticipated, they rose considerably versus Q1, 2022, reflecting reduced commercial spending early last year, the inflationary climate, the timing of costs, and commercial investments made up front. We keep getting good results from our cost-cutting efforts, which lets us keep putting money into the business and helps offset rising prices. In Q1, we achieved $150 million in gross savings, and close to $50 million of that came from SG&A. The important thing is that over the remaining months of the year, we expect SG&A growth to slow down considerably, dropping below the rate at which net revenue grows — and that ought to give OI margin a boost. That brings me to our 2023 projections. Given how strong Q1 was, we have clear visibility into robust growth for the entire year. We still expect organic top-line growth between 7% and 8.5%, and for HTU, shipment volume growth is aimed at speeding up compared with 2022. The rest of our operating assumptions remain the same as what we published in this morning's press release. Also, remember that for most of the year, Swedish Match doesn't factor into our organic numbers at all. Our updated guidance for full year adjusted diluted EPS sits at $6.10 to $6.22, and that figure bakes in an estimated 30 cents of negative currency effects. We're seeing gains from the Euro and a few other currencies, but those are outweighed by the weak Japanese Yen, along with significant declines in the value of the Russian Ruble and the Egyptian Pound. That range still reflects 7% to 9% growth on a currency-neutral basis, and it leaves out any benefit from a possible favorable excise tax ruling in Germany, which we'd anticipate adding roughly 3 points to our adjusted diluted EPS tied to 2023 tax payments.
Emmanuel Babeau
executiveOur projection remains that Swedish Match will add low single-digit accretion to adjusted diluted EPS for 2023 once financing is accounted for, alongside a rise of roughly $200 million in interest costs unrelated to acquisitions, even though Q1 brought only a fairly small step-up. As we covered during February's full-year earnings discussion, bottom-line results for this year should be heavily tilted toward H2. That said, we anticipate organic net revenue growth picking up as soon as the second quarter, reaching the high single-digit territory; for Q2 we project HTU shipment volumes ranging from 30 billion to 32 billion, with adjusted diluted EPS between $1.42 and $1.47, a figure that incorporates an anticipated currency drag of 13 cents. Turning to the back half of the year, we look for organic top-line growth near double digits and for margins to expand once again. Viewed from another angle, our full-year outlook calls for very strong results over the remaining months following the transitory pressures of Q1. Notwithstanding persistent margin pressures and continued investment, we anticipate organic top-line growth between 8% and 10%, better margins with expansion during H2, and currency-neutral adjusted diluted EPS growth of 10% to 13%. This mirrors the powerful underlying forces behind our transformation, as IQOS and ZYN push volumes upward at a greater net revenue per unit, paired with higher pricing on combustibles. Returning to Q1, our HTU adjusted IMS volumes rose an estimated 16%, which shows sustained robust momentum. At 27.4 billion units, HTU shipments landed near the upper bound of our projected range, up 10.4%, a pace considerably under actual offtake patterns as we had expected, owing to inventory shifts among distributors and wholesalers. As our full-year HTU shipment guidance implies, we look for shipment growth to quicken over the balance of the year as shipments align with consumer offtake, expanding more rapidly in 2023 than was the case in 2022. Prior to walking through these inventory effects, one point deserves emphasis: in some markets, Germany among them, IMS sales volumes aren't captured at the stage where distributors sell to retailers, since such data isn't obtainable; for those markets we rely on our shipments as the proxy instead; consequently, shipment swings can affect both IMS volumes and reported market share, and might not reflect true offtake dynamics. In light of the volatility witnessed this quarter and going forward, whenever a meaningful gap appears between estimated offtake performance and IMS data, we might opt to report market share metrics derived from adjusted IMS so that offtake is better represented, with those adjustments capturing the full estimated effect of inventory movements by distributors and wholesalers. As today's earnings release appendix likely shows you, that applies to Germany in this quarter, and we supply historical figures there as well. Back on Q1, HTU shipment volumes across a number of European markets came in under consumer offtake. The reason for this comes down to unwinding certain inventory that had been built up late in Q4 2022 — partly to support ILUMA launch requirements, which we discussed during February's full-year results, and partly to hold a bit of safety stock against possible production and distribution disruptions stemming from energy shortages. Just as we expected, we managed to bring that safety stock back down during Q1 once the threat eased; on top of that, we trimmed IQOS blade HTU inventory levels in a number of markets so as to lower the chance of obsolete stock, given how quickly the shift to ILUMA is happening. Among the markets notably affected are Italy and Germany, where underlying share and offtake momentum stayed solid. Italian Q1 IMS volumes were up 21% year on year, and share climbed to 17.4% in Q1 from 15.4% in Q4. In Germany, adjusted Q1 IMS volumes rose more than 30% versus a year earlier, while adjusted share went from 4.7% in Q4 to 5.3% in Q1. Returning to the broader view, although combined Q1 cigarette and HTU shipment volumes fell 1.1%, our total IMS volumes came in essentially flat and posted growth when total estimated inventory movements are excluded. Cigarette shipments were down 3.1%, though trends stayed resilient across many markets. That decrease reflects a sizable hit from a tough prior-year comparison in Japan, plus the sudden excise tax hike in Pakistan, which fueled illicit trade and shrank the industry by more than 30%. Volumes also fell in the Philippines after industry pricing actions, with consumer purchasing power still under pressure. Our target remains stable to positive combined cigarette and HTU shipment volumes for the year, after growth in 2021 and 2022. That figure notably leaves out the outstanding growth potential of oral nicotine, whose shipment volumes rose 10% in Q1. Above all, the powerful growth pairing of IQOS and ZYN offers an unmatched platform for expansion in the years ahead. Turning to combustibles, our portfolio posted solid Q1 organic net revenue growth of 3%. That mirrors robust pricing of 7.4%, with an uplift across numerous markets such as Germany, Indonesia, and the Philippines. Since more than 80% of planned 2023 combustible pricing has been implemented or announced, we have solid visibility on full-year delivery, even though part of the favorable Q1 variance comes from pricing taken earlier than in 2022. We now project a full-year variance of 6% to 7%. Our cigarette category share slipped 0.3 percentage points in Q1, essentially all of it due to geographic mix, as the total industry shrank in large volume markets like the Philippines and Pakistan. Share movements within markets had a neutral effect, as gains in places including Egypt, Poland, and Turkey were offset by declines in markets such as Ukraine, the Philippines, and Iraq. Importantly, we still aim for a stable category share in 2023 and over time, notwithstanding the impact of IQOS cannibalization. Switching to our smoke-free products, we estimate 25.8 million IQOS users as of March 31st. We've seen an increase of nearly 1 million adult users compared to December, with especially encouraging movement in Japan and Europe, along with many other regions. Across a wide set of markets where it has launched, IQOS ILUMA has acted as a favorable driver of both volume and share expansion, reinforcing our leading position in heat-not-burn through an improved user experience while also helping the category grow further. Among current IQOS users, ILUMA prompts a faster upgrade path. That strengthens retention and supports full conversion going forward, though concentrated device sales create a short-term effect on margin. In fact, we're nearing an estimated 10 million ILUMA users, and ILUMA now accounts for more than 85% of HTU volumes in the earliest launch countries — Japan, Switzerland, and Spain. ILUMA is additionally improving how we acquire and convert legal-age smokers, with share momentum apparent both in earlier markets and those launched more recently, like Italy and Korea. Following the Q4 introduction in those two markets, we're observing promising signs in the initial launch areas and anticipate this becoming more evident nationally over time, as has happened in Japan and Greece, the latter following a seasonal inflection.
Emmanuel Babeau
executiveDuring Q1, our primary objective was making sure ILUMA succeeded across the 16 markets where it had launched by the close of 2022 — those markets account for more than half of our IQOS business measured by volume. Beyond that, we introduced ILUMA in Indonesia on a limited basis during February through our IQOS club members program. That club dates back to 2019 and currently counts over 100 thousand estimated users spanning 10 cities, helped considerably by ILUMA's arrival. We anticipate rolling ILUMA out progressively into additional markets over the course of this year. Since ILUMA is speeding up IQOS expansion wherever it has debuted, PMI HTUs keep reinforcing their standing as the second biggest nicotine 'brand' in markets where IQOS exists, hitting a record 9.0% share in Q1. Even more striking, by Q1 PMI HTUs have become the leading nicotine brand across 10 markets, with Italy and Greece joining that group during the quarter. Turning to Europe, which under our revised regional setup takes in extra markets including Ukraine. Our HTU share for the first quarter climbed 1.7 points, arriving at 9.2% of overall cigarette and HTU industry volume, adjusted for estimated wholesaler and distributor inventory movements like the ones I referenced earlier in Germany and Italy. On that same adjusted footing, IMS volumes kept rising sequentially, setting a record 11.1 billion units on a four-quarter moving average. This captures solid advancement throughout the region. We foresee our Europe HTU volumes expanding robustly over the rest of the year, though, as has happened before, seasonality in cigarette consumption during Q2 and Q3 can affect our quarterly HTU market share. For additional insight into our excellent regional progress, slide 16 presents a sample of the newest key city offtake shares. IQOS keeps succeeding across a wide variety of geographies — Western, Southern, Central and Eastern Europe — including markets both with and without ILUMA. Standouts worth noting include Budapest at above 35% offtake share, along with Rome and Athens hitting the high twenties. Returning to what I said earlier, we're highly pleased with results in Germany, where Munich's offtake share exceeded 10% for the first time. We're likewise heartened by recent favorable regulatory movement in Greece, where the Ministry of Health granted approval for differentiated health claims covering heated tobacco products. Greece becomes the first nation outside the United States to allow healthrelated statements after a rigorous scientific evaluation. In Japan, heat-not-burn now makes up more than 35% of all tobacco, with IQOS fueling category expansion. The acceleration observed over recent quarters carried into Q1. Adjusted total tobacco share for our HTU brands rose 3.4 points to 26.2%, with offtake share exceeding 32% in Tokyo and 30% in Sendai. Adjusted IMS volumes once again grew sequentially, hitting a record 9.0 billion units on a four-quarter moving average. Japan's strong results underscore once more how vital continuous innovation and a wide-ranging consumable portfolio are. During Q1, our TEREA HTUs, which carry a premium price, along with our mainstream-priced SENTIA HTUs, kept expanding, reinforcing their standing as the top two heat-not-burn brands. The advances we've made in Japan make us very happy, and while we anticipate continued solid growth in volumes over the quarters ahead, we'd also like to flag how seasonality affects quarterly share metrics. Beyond the strong IQOS momentum in developed markets, we keep witnessing highly encouraging expansion in Low and Middle-Income markets, which are now nearing 30% of all our HTU volumes. This slide spotlights a handful of Q1 key city offtake shares from markets spanning Eastern Europe, the Middle East, Asia and Latin America. Standout wins include Bulgaria, where Sofia offtake share exceeded 16%, and Egypt, where Cairo's offtake share hit 7.5%. Across these vital markets of the future, we likewise keep observing sturdy offtake volume growth. Turning next to Swedish Match's business, it turned in a superb Q1, posting currency-neutral net revenue growth of 14%, with smoke-free products accounting for 77% of total net revenues. What stood out most was ZYN's ongoing exceptional U.S. performance, with volume up 47% to 73 million cans. Although inventory movements, among them restocking in California after December's flavor ban, gave volume growth a lift, the underlying volume expansion was extremely robust, estimated at well above 30%. We're equally happy with how other U.S. smoke-free categories performed in Q1, moist snuff among them, which picked up 0.8 percentage points of category share and posted shipment volume growth of 3%. Scandinavia's smoke-free category kept expanding on the back of nicotine pouches, though at a slower pace after January's snus excise tax hikes in Sweden and Norway, with destocking deepening the volume drop for Swedish Match's premium-skewed snus portfolio. In cigars, the business posted positive pricing and sturdy shipment volume growth of 4% within a shrinking category, powered by strong development of natural leaf varieties. Last, I want to congratulate Swedish Match's employees for consistently delivering excellent results as we carefully integrate our activities. Integration is moving along very well, and we look forward to sharing more about our combined growth plans later this year; now let's dig deeper into how ZYN has performed recently in the U.S. Excellent momentum continues, with a record gain in 12-month rolling shipment volumes of 23 million cans, equal to 40% growth. Category volume share stayed basically flat even as heavy competitive discounting from less premium offerings persisted. Crucially, ZYN's retail value share also stays solid at 75.6%, underscoring its premium positioning and superior brand equity. As covered at CAGNY, two key engines power ZYN's U.S. growth. The first is the steady expansion of distribution, with store count 13% above Q1, 2022 at roughly 140,000. There's still plenty of room to grow this further over time. The second is velocities, meaning the number of cans sold per store per week. ZYN's momentum keeps building quarter over quarter, and it's up a remarkable 21% versus the same period last year, showing that adult nicotine users keep connecting with the brand. Let me now bring you up to speed on the ambitious initiatives we have to push our smoke-free ambitions even faster. As we've said before, getting IQOS ILUMA out across the entire world is a top priority. Thanks to HTU production bottlenecks continuing to loosen, we expect to deliver meaningful advances during this year. Our work continues on the plans to commercialize IQOS in the U.S., aiming for a Q2 2024 launch, consistent with the approach we laid out at the recent CAGNY conference. Having gained know-how and commercial capabilities from bringing IQOS to success in more than 70 markets internationally, along with a U.S. marketplace that offers a well-defined regulatory environment and the capacity to engage with adult smokers, we stay highly optimistic about what's possible. Crucially, we think we're able to put the required funding into the U.S. business, which will drive extra top-line results while we keep producing robust bottom-line expansion for PMI throughout the investment window. Beyond what we offer at the premium end, we maintain our focus on BONDS, our newest heat-not-burn product, which holds particular appeal for Low and Middle-Income shoppers. The pilot rollouts in the Philippines and Colombia are moving along nicely, and we plan to keep absorbing what these markets teach us prior to expanding more broadly.
Emmanuel Babeau
executiveOne more significant medium-term prospect stemming from the Swedish Match deal involves taking nicotine pouches global, especially ZYN — the number one brand worldwide. During CAGNY, I noted our aim of as many as 10 launches or relaunches during this year as we work to build the category among adult smokers who appreciate the ease, particular usage moments, flavor, and gratification. We anticipate kicking this off in a handful of markets during the summer, spanning mature as well as developing nations. Although we remain plainly concentrated on the heat-not-burn and nicotine pouch segments, since those offer the biggest and most value-enhancing growth chances, we are reworking our VEEV e-vapor lineup and strategy. Our plan is to concentrate on selling in chosen markets and putting profitability first, in light of the well-known difficulties in that category. VEEV ONE is a fresh pod-based device delivering a better consumer experience, with production of both hardware and consumables entirely contracted out to keep costs down. VEEV ONE is set to take the place of the existing VEEV offering, and because of that, we will not submit a PMTA for the earlier technology. Rather, our short-term FDA interactions will center on IQOS and ZYN; we will address upcoming e-vapor FDA authorizations at the appropriate time. Regarding disposables, the e-vapor segment expanding most quickly, we are changing the VEEBA name to VEEV NOW. Every one of our e-vapor offerings will sit beneath one easily identified brand, VEEV, to deliver a smooth consumer experience. We will bring out the new VEEV ONE platform in Canada before this month ends and will take a nimble, disciplined tack for additional VEEV launches before this year is over. Turning to sustainability, let me begin by pointing you to our 2022 Integrated Report, which came out earlier this month and lays out the headway we are making toward fulfilling our purpose and smoke-free future. That report walks through all our most significant sustainability subjects in thorough fashion. That takes in the ones investors are watching closely, like post-consumer waste, stopping youth access, decarbonization, and how we direct resources toward pushing our smoke-free transformation forward. Alongside the Integrated Report, we also put out a refreshed ESG KPI Protocol, giving stronger standards for defining success and gauging ESG performance. It centers on the KPIs inside our Sustainability Index, which, as stated in our 2023 proxy statement, still make up 30% of our long-term performance-based equity compensation for executives. I am delighted as well to share that we issued our inaugural TCFD Report yesterday, which refreshes and gathers our earlier disclosures regarding how we are carrying out the recommendations of the Task Force on Climate-related Financial Disclosures into a single document. This will matter greatly to numerous companies as reporting rules keep shifting. Finally, we are glad that, after CDP’s triple A recognition, PMI once more earned a place on CDP’s supplier engagement leaderboard, helping us move toward our scope 3 ambitions. To wrap up today’s presentation, we remain positioned for robust results in 2023 in spite of margin headwinds. Our underlying growth fundamentals stay solid, and we anticipate those headwinds will steadily diminish as the year goes on. Sure, our Q1 numbers came in above what we had projected, and that keeps us on pace to achieve high single-digit organic net revenue growth for a third year in a row. IQOS and ZYN kept performing extremely well, which strengthens our standing as the worldwide leader in smoke-free products, with top positions in heat-not-burn, the biggest category, and oral nicotine, the category expanding most quickly; through combustible pricing and our cost savings programs, we're acting to offset cost inflation, while we move swiftly toward our goal of becoming a business that is majority smoke-free. And lastly, we continue generating substantial cash and hold an unwavering dedication to our progressive dividend policy. As our transformation produces sustainable growth, we anticipate rewarding shareholders even more. Thank you. We're now glad to take your questions.
Bonnie Herzog
analystThank you. Hi, everyone.
Emmanuel Babeau
executiveGood morning, Bonnie.
Bonnie Herzog
analystHello. So I have something to ask regarding the guidance you've provided for Q2 — it appears somewhat softer at present, which suggests a larger portion of the expansion is anticipated in the latter portion of the year. So I'm simply attempting to understand how cautious that Q2 outlook may be? And then truly, Emmanuel, what degree of visibility and assurance do you possess that your business can genuinely speed up and exceed expectations during the second half? Perhaps you might point out for us a few of the main positives and negatives behind that confidence, and perhaps where you perceive the largest possible upside, plus some detail on < >
Emmanuel Babeau
executiveAll right. Certainly, Bonnie, glad to do so. And I suppose thank you for asking, since that allows me to make clear the timing of profit generation during this year. I believe we aren't introducing any new approach compared with what we stated in February; we consistently indicated that during the first half of the year we would confront several profitability headwinds, that certain inventory movement would be at play. We pointed that out and we plainly stated margin improvement would arrive in the later portion of the year, and today we bring precisely the same message. We're happy to report a Q1 exceeding what we initially expected. We never provided guidance before today concerning Q2, yet I believe what we now observe for Q2 arrives with numerous favorable elements. We're clarifying that we do anticipate faster top-line growth; we're referring to high single-digit expansion as our target for the second quarter, and naturally that will deliver a very good contribution to second-quarter performance. That underscores the momentum present in our business, which we see behind IQOS, and it doesn't capture ZYN's growth for the second quarter. Thus ZYN merely arrives as an addition to that organic growth. So I believe it conveys a sense of how well established and vigorous our business is. Now regarding margin, it's accurate that once more in Q2 we will encounter several headwinds, particularly at the gross margin level; so we will keep experiencing multiple effects stemming from inflation. This will be gradually rectified, yet I think you ought to anticipate one more quarter where the gross margin rate falls substantially compared with 2022. And afterward the latter portion of the year will once more display improvement, consistent with our original thinking. Where I suppose you will begin observing somewhat more favorable effects in terms of margin movement, that's on the revenue — pardon me, the SG&A to revenue ratio, where deterioration occurred in Q1. What I'm really trying to convey is that I'm not promising SG&A will increase more slowly than revenue during Q2. What I do anticipate is that in Q2, SG&A growth will come nearer to revenue growth, which means its drag on the operating income margin will be smaller. Still, that is genuinely what you ought to anticipate when it comes to how the year unfolds. Once more, we're looking for a very strong pickup on the top line, which simply validates the solid momentum the business is seeing, and the margin ramp-up is arriving gradually. It will appear initially in the relationship between SG&A and revenue. And during H2, as we've stated, we anticipate an improved trajectory for the gross margin rate. At this point, we are merely reaffirming our original expectations.
Bonnie Herzog
analystNo; that's really useful, and it sounds like you have pretty solid visibility there. So yes, that definitely helps; and then, I suppose, maybe just a quick big-picture question about how healthy the consumer is in, sort of, your main markets. Could you kind of speak to that for us? And then, with that in mind, you've obviously been implementing stronger pricing on combustible cigarettes. So I'd just love to hear a bit more detail on how consumers have been reacting to those moves and really how confident you feel that you'll be able to keep pushing that pricing through for the rest of the year? Thanks.
Emmanuel Babeau
executiveYes. I won't claim that we see no pressure on the consumer anywhere in the world. It's quite evident, and naturally you're not referring to the U.S., which — perhaps that warrants a separate remark; but it's clear that in countries like the Philippines, for example, we observe some effect on the business stemming from purchasing power. I believe we see a bit of that in Indonesia too. So those are markets where pressure on purchasing power already existed, particularly resulting in some downtrading, and that has kept playing out as we moved through the start of 2023. But I must say that in many markets, we haven't observed clear signs so far. We have to remain very cautious, of course, about pressure on the consumer, all your massive downtrading. We don't see that. Marlboro's market share was slightly down, but I don't think that clearly reflects at this point a strain on the premium product in our portfolio; and we've been raising price, as you've seen, in a very significant way. Naturally, competition not immediately or not entirely responding to our price increase can have an effect on our market share, but I would say so far, we have the feeling that in a highly inflationary environment, the consumer is behaving as normal and doesn't see it as a problem to also see a price increase on his tobacco product.
Bonnie Herzog
analystOkay. That context is helpful, Emmanuel — thanks.
Emmanuel Babeau
executiveYou're welcome.
Gaurav Jain
analystHello there, and good morning. I appreciate you allowing me to ask my questions.
Emmanuel Babeau
executiveMorning to you as well, Gaurav.
Gaurav Jain
analystGood morning. My first question concerns foreign exchange. Back in February, you were pointing to a $0.15 headwind. At this point it stands at $0.30. The Egyptian pound lost value during January, and sure, the yen has slipped somewhat, yet the euro — a far more significant currency in your case — has risen by even more than that. The ruble surely isn't that large, is it? Or has it grown more important this year compared with last year? Could you walk us through how this works?
Emmanuel Babeau
executiveCertainly, Gaurav. You correctly zeroed in on the ruble. We won't break out currencies one at a time, but when you examine the ruble alone, it accounts for a bigger amount than the entire net effect of $0.30 we now expect for this year. That demonstrates just how powerful the ruble's influence is. Meanwhile, the Egyptian pound kept losing value past January. I can't be certain we've captured its complete effect. In fact, combining the ruble with the Egyptian pound gets you to 80% of that $0.30 net effect — and I do mean net. Don't misunderstand me, since the yen is also quite unfavorable. On the other side, the euro along with several other categories works in the positive direction. Still, the ruble plus the Egyptian pound together give you a solid account of that net effect. I trust this answers your question.
Gaurav Jain
analystAlright, got it. Turning to the second point — at the industry level, U.S. cigarette volumes look pretty soft, down 9%; then when I look at the European figures you gave, industry volumes there are flat against what were already really tough comparisons. And the explanations that have been offered for the weakness in the U.S. industry — macro pressures, a stretched consumer, stimulus payments ending, growth in disposable e-cigarettes — I could just as easily apply that same reasoning to the EU consumer, the EU smoker, and yet volumes there are performing far better than the trend would suggest. So is there — could you walk through why the U.S. smoker and the EU smoker are behaving in such different ways?
Emmanuel Babeau
executiveGaurav, I can't — and I should acknowledge that I'm hardly the foremost expert on the U.S. consumer when it comes to combustible cigarettes. So I ask myself the same thing when trying to analyze it. I believe it fits with what I said earlier, namely that up to now, the consumer in Europe has held up fairly well against the same sort of price increases and has managed to cope with inflation. Why there's a divergence here, I'm unable to say. It's clear the social model in Europe works differently. There may be greater protection, more of a safety net at play, and that could be blunting the effect of inflation. Possibly there was more offset provided by various governments attempting to counter the rise in energy prices and at times offsetting inflation in agricultural products in a number of geographies. So that might be one factor explaining why the European consumer is holding up better; but I won't claim to possess the definitive answer to what you're asking.
Gaurav Jain
analystOkay, thank you so much.
Emmanuel Babeau
executiveThank you.
Pamela Kaufman
analystHi, good morning.
Emmanuel Babeau
executiveGood morning, Pamela.
Pamela Kaufman
analystI was hoping you might go into a little more detail about the SG&A investment you're making this year? Which areas matter most when it comes to where that money is going, and what's behind the step up we saw in Q1? I suppose what I'm trying to figure out is how much of that comes from structural inflation pushing costs up, versus the extra spending you're putting behind ILUMA, Health and Wellness, and Swedish Match?
Emmanuel Babeau
executiveOnce again, I'll go as far as I possibly can — as you'd expect, certain parts of this are extremely sensitive, so we won't get into the specifics of what we're investing and where. To begin with, let me try to frame things for the full year: we think our SG&A will increase more quickly than revenue on an organic basis; even so, we anticipate only a modest gap between those two figures; which means that as we move through 2023, you ought to see our SG&A growth come together with top line growth — I'm referring to organic here; and Q1, I'd say, is genuinely affected by several one-offs, both, incidentally, when it comes to the comparison base — if you examine our Q1, Q2, Q3, Q4 figures from last year in sequence, you'll notice Q1 was quite low, partly because our investment didn't land at that same point in the year. So investment has a phasing pattern, and partly because there was a favorable one-off last year, so Q1 shouldn't be treated as a benchmark. That said, inflation is something we're dealing with, naturally, in our SG&A. People cost makes up a large portion. And naturally, salaries are going up. But we're also, in fact, producing some efficiencies. That gives us a bit of room to put money into what we prioritize. It concerns, naturally, commercial spending on our priorities, as you'd expect. So it all goes toward marketing and commercial efforts to boost IQOS. That's obviously a major driver. It's the spending we're making to get the U.S. ready. We've discussed the spending we're making in Wellness and Healthcare. We keep innovating heavily. We have innovation in the pipeline across all our smoke-free products. And naturally, that has an effect too. So that's really what's behind this growth, and we continue to view as important this ability we have to handle inflation, to invest for the future and, at the same time, to have an SG&A trajectory that, thanks to the business's dynamism, still lets us deliver solid operating income and net profit growth. That's what I'm able to share with you.
Pamela Kaufman
analystAll right. Thanks. Next, could you discuss the shift in your e-cigarette approach? What drove this move toward the IQOS perspective? Also, how do you view this segment over the long run, and what role will you play in it?
Emmanuel Babeau
executiveWell, I believe we've made it plain already that although we were definitely building out certain products within vaping, that wasn't where our focus lay. IQOS was ours. At this point, I'd say two things have captured even more of our attention: IQOS and ZYN. When your team is this outstanding and holds the capacity to generate extremely robust top line expansion, volume expansion, revenue expansion, all in a highly profitable manner, that truly becomes what you prioritize. You probably heard from us at CAGNY about the doubts we hold regarding vaping as it stands, involving the lack of unambiguous rules across numerous nations. This situation is enabling unsuitable promotional practices, plus the danger of minors using these products; and additionally, this remains a segment where thus far it's challenging. I won't call it unachievable, yet challenging to identify many profitable frameworks being built. Consequently, this drives us to examine that space and keep working within this segment, and the arrival of this range update, I believe, simply aligns with how technology keeps advancing; we observe shifting consumer requirements too, which explains why VEEV is being created now; however, our efforts will stay concentrated; so it won't span every market; it will be limited to places where vaping matters. It will be limited to places where we can stand apart and possess the commercial muscle to create real traction. And I believe pursuing that path is far superior — nurturing a handful of wins rather than draining our resources attempting to build something worldwide right now, when the necessary elements for making that occur in a compelling way, regarding both growth, top line and bottom line improvement, aren't clearly present.
Pamela Kaufman
analystThanks. That’s very helpful.
Emmanuel Babeau
executiveThank you.
Vivien Azer
analystHi, good morning.
Emmanuel Babeau
executiveGood morning, Vivien.
Vivien Azer
analystTo start, I'd like to ask something that builds on what Gaurav raised. Regarding the FX guidance you're currently giving, is a further devaluation of the Egyptian pound baked into it? From what I gather, at this stage that's widely anticipated.
Emmanuel Babeau
executiveNo, it isn't, since naturally we have no clue how large it might be or when it might occur. What we're really doing is taking an average based on the spot rate from the day prior to the announcement, and we aren't factoring in any forward-looking view or consensus forecast about where currencies might move. Plenty of people right now think the euro is headed for a significant gain versus the dollar over the next few months. Honestly, we aren't wagering on any potential movement at all — we're simply going by the spot rate.
Vivien Azer
analystAll right, that's reasonable. I get that forecasting currencies isn't what you do. It simply appears connected to the IMS bailout. So that seems logical to me. Then my next question concerns Swedish Match's margins, which arrived rather strongly. I was wondering, because of the extra inventory gain you had in California, how ought we to view the 1Q margin relative to a normal margin? Did an additional margin gain exist that we should mentally remove when considering what profitability level suits that business? Thank you.
Emmanuel Babeau
executiveWell, Vivien, what I'm able to tell you, I think, is that Q1, in my view, is simply clear proof of what we stated, meaning Swedish Match brings a strongly accretive effect on PMI's growth. That holds for volume, holds for revenue, holds for profitability. So yes, ZYN is expanding in the U.S. quite well, and I won't revisit this growth above 30% excluding California's effect. That propels a business that's quite profitable, one that's accretive on its own to Swedish Match's average business. And so, naturally, to PMI; and having this growth engine is simply excellent news. Honestly, I don't wish to say the same thing again, but IQOS plus ZYN, that's simply a really thrilling combination, and ZYN plays a great top-line and margin-boosting part, and we anticipate that continuing.
Vivien Azer
analystUnderstood. Thank you very much.
Emmanuel Babeau
executiveThank you.
Andrei Condrea
analystAndrei Condrea here — Emmanuel, hello, and I appreciate you fielding my question.
Emmanuel Babeau
executiveAndrei, hey there.
Andrei Condrea
analystHello, I've got a couple of questions for you, if that's alright. First, regarding the rise in input costs. Clearly, your ILUMA margins are set to gain from efficiencies that arrive later in the year. Yet when it comes to the other headwinds you mentioned, leaf and acetate tow, can you offer any detail on the scale of those headwinds?
Emmanuel Babeau
executiveThey're extremely significant, and we did highlight that. As I believe we also explained during Q1, we anticipate the same pattern carrying into Q2. The sharp climb in energy prices, leaf prices, and acetate tow will be the primary force behind the squeeze on gross margin. As we move into the second half of the year, particularly near its close, we think these factors will be — well, to start with, we'll already be confronting some of that unfavorable news in H2. Naturally, then, the comparison from one period to the next will be simpler. Meanwhile, we continue focusing on productivity. We'll keep addressing our COGS to capture every optimization. So this downward pressure won't vanish entirely, though it should soften relative to what we're seeing in H1. Still, for Q2, I'd anticipate the pressure staying very intense at that same level.
Andrei Condrea
analystGot it, that's quite clear, thanks. Now for my next question, which looks further out. Naturally, a competitor of yours unveiled something new during its Investor Day aimed at the U.S. nicotine pouch market. Meanwhile, other companies in your peer group are launching their European offering. Given the complaints — or rather, the downside — that ZYN is a far drier product compared with the — right. Could there be room for comparable innovation around ZYN?
Emmanuel Babeau
executiveRight. Through Swedish Match, I'd say we hold the largest dedicated, highly focused, deeply expert participant in oral nicotine. On top of that remarkable expertise, we've layered the 13 — as you might recall, we acquired that business, which specializes in formulating products, some containing nicotine, and it can deliver really appealing innovation when it comes to form factors too. So, expect something from us. Naturally, you shouldn't count on me revealing specifics, yet you can definitely count on us delivering appealing innovation. In certain areas, consumers clearly have an appetite for experimenting with new options, new < > products, to grow this oral nicotine segment into additional spaces. The consumer probably isn't fully aware of what's achievable, so it falls to us — it's our obligation — to step forward with some proposition. Still, I imagine you can count on us, and I believe we've shown that PMI — and now within PMI, together with Swedish Match — leads innovation in this category going forward as well.
Andrei Condrea
analystFantastic. Thank you very much.
Emmanuel Babeau
executiveThank you.
Matt Smith
analystHi, thank you for the question.
Emmanuel Babeau
executiveHi, Matt.
Matt Smith
analystDuring Q1, the sequential gain in IQOS users climbed to roughly 900 million more. Could you share additional color on the positive conversion patterns you've observed with ILUMA? Also, as ILUMA capacity increases and you widen the product's geographic reach, ought we to anticipate faster IQOS user expansion in the back half?
Emmanuel Babeau
executiveThanks; indeed, in Q1 we added nearly 1 million IQOS users. That's a solid figure. It isn't a level we can surpass. I believe there's room to speed up further as we move through Q2 and later; however, before anything else, I'd like to offer a note of caution. This isn't a rigorous figure — it's an estimate — and it may shift somewhat based on several factors; still, in terms of direction, I think it's accurate, and I think it demonstrates IQOS's very powerful momentum. Naturally, this is corroborated by the consumer offtake we've described. Clearly, ILUMA is aiding that conversion. What we observe with ILUMA is a greater ability to persuade smokers, since the experience is smoother. No cleaning is needed. It aligns even more closely with the combustible cigarette ritual. The total experience feels more fulfilling. As a result, the rate of abandonment is reduced. Naturally, since we're discussing net user acquisition, that also contributes; we're seeing quite good improvement in consumer satisfaction across every country. That, I'd guess, is likely underpinning the reduced abandonment. So clearly, the further we shift toward ILUMA, the more capable we become of speeding up conversion. Japan, I believe — well, we're presenting a figure for Japan and you can trace the history. Japan, I think, is supplying plenty of valuable insight, since it required some time. The pickup we've had since Q3 in Japan is honestly rather remarkable, and it likely surpasses what we anticipated. Yet it demonstrates that ILUMA is perhaps steadily gaining traction through, I don't know, word of mouth. And — yet consumers are coming to see that this makes a major difference. And honestly, the surge in market share to above 26%, and I'm not referring to Tokyo, but the average Japanese market share, marks a substantial acceleration; it began in Q4, yet it sped up, and that's one year following the launch. So it demonstrates that not all developments occur in the launch's first quarter. I think we're displaying a set of charts here that illustrate that. And that suggests a favorable ramp-up in the quarters ahead, since not only must we begin launching ILUMA across a number of countries, but we also know this beneficial effect will extend through the quarters ahead; so we regard that as a strong driver for user acquisition growth in the quarters ahead.
Matt Smith
analystYes. Thanks for laying that out; and I'd like to ask something else regarding a point you brought up during this call about keeping profit growth going in the U.S. while IQOS is being rolled out. Could you describe what's required on the investment side in the U.S. to make commercialization work? And also, how does roughly $75 million of spending in 2023 in this area start constructing the infrastructure that a wider IQOS launch will need?
Emmanuel Babeau
executiveYes. So that figure represents the extra investment. Naturally, though, we already have certain investments underway in the U.S.; when the Investor Day arrives in September, we'll present a thorough roadmap for how IQOS is meant to expand across the U.S. At that point, naturally, we'll give far more detail regarding the amount of investment we expect will be required. I believe the key takeaway — since many questions have come in on this — is that yes, naturally, if we're going to unlock what we regard as IQOS's tremendous potential in the U.S., investment is going to be necessary. Incidentally, we've put money in over the years to establish that extraordinary IQOS business in Japan and Europe. In other words, investment has been happening. It wasn't luck. So investment in the U.S. will happen too. What we observe, though, is that because of the growth momentum present in the business, we believe putting money behind IQOS in the U.S. will, above all, deliver still more momentum at the top line, and that this investment can be absorbed even as the bottom line keeps expanding quite well. We won't accept a trade-off on bottom line growth just because of the investment required in the U.S. To restate a point I've made before, I think what remains open is this: how much of a gap can we create between top line growth and bottom line growth? Keep in mind, the prior algorithm was 5% and 9% — above 5%, above 9%. Now, should we push the gross rate outlook beyond 5%, that doesn't automatically mean a 4-point gap between top line growth and bottom line growth will be maintained. That captures what those comments meant. I hope that answers it.
Matt Smith
analystVery helpful. Thank you very much.
Emmanuel Babeau
executiveThank you.
Jared Dinges
analystYeah, hey everyone. I'd like to ask about how ZYN is growing in the U.S., since it looks like it actually sped up in the offtake data, even while the base keeps expanding, and that base is quite large at this point. Do you see any upside there from the spending you began committing as part of getting ready for IQOS, maybe in terms of constructing a sales network? Are you also boosting SG&A spending specifically on ZYN? I'm looking at this through the lens of the brand getting larger, and we can see the cigarette numbers have obviously been quite soft, yet the momentum keeps performing strongly; so I'm simply trying to figure out what's actually behind that?
Emmanuel Babeau
executiveThank you, Jared, for asking. Well, to begin with, yes, naturally, we're very happy with how ZYN is doing in the U.S. And I'd like to recognize the effort the team there is putting in, which is truly outstanding. No, I don't believe there's a meaningful effect yet coming from what we've invested in the U.S. I'd say it's growing thanks to a strong commercial strategy and execution. This brand has incredible momentum. In my view, consumers hold it in very high esteem as a premium brand, a really attractive franchise; and they're advancing on those two fronts, as described, one being geography. The second is consumption per store. Let's just highlight those two points. First, obviously, we've expanded the geographic footprint fully; and that's likely where, over the next few quarters, you'll notice some pickup as we add more people in the field and greater ability to call on retail outlets. And secondly, there's expanding awareness, comprehension and desire for the category and for ZYN, which embodies the category, and that's what we're observing; so up to now, no truly added spending beyond the organic rise, because when you have such strong growth, naturally, spending goes up versus the prior year. So yes, we are raising investment in the U.S., but nothing like an accelerated program at this point, and no effect yet from IQOS investment, which ought to arrive later.
Jared Dinges
analystPerfect. Thank you.
Emmanuel Babeau
executiveThank you.
Priya Ohri-Gupta
analystHi, and thank you for fitting me in. Emmanuel, I was hoping we might spend a moment on how your cash flow did during the quarter; from what I gather, the softness had something to do with timing, since the first quarter is always your weakest seasonally; even so, could you take us through what was behind that negative figure for cash flow from operations?
Emmanuel Babeau
executiveYes, of course. You're right that cash flow performance in Q1 was not great; but once again, this had been anticipated. It relates to when shipments occurred, excise duty payments and certain working capital items. Nothing caught us off guard. I'd certainly rather have seen stronger operating cash generation in Q1, though it was anticipated. And we fully reaffirm our target for the year: operating cash flow of between $10 billion and $11 billion.
Priya Ohri-Gupta
analystAll right. Next, a small administrative matter. Could you provide the pro forma leverage, factoring in what Swedish Match contributes, across a complete 12-month period, compared with the figures as reported that appeared in the release?
Emmanuel Babeau
executiveNo, my belief is that it wasn't included in the release. Whether we will share that, I can't say. Still, I mean, you're able to derive it. I'm not certain I fully grasp what you're asking — I think the data needed for those calculations is in your hands, though you're welcome to follow up with us, and we'll determine if we can point out where such information can be found.
Priya Ohri-Gupta
analystAbsolutely. My view is that when you factor in a complete year of Swedish Match's contribution, the step-up in leverage on a sequential basis lands nearer to roughly 0.2 of a turn, rather than the larger number that came through in the reported directional figure.
Emmanuel Babeau
executiveNo, what I believe you're pointing to is the reality that when we wrapped up 2022, we said we sit at approximately 2.9 times, though naturally that number would come in lower, and notably lower at that. And perhaps it's roughly in line with what you're observing in this instance, were you to include the entire year of Swedish Match.
Priya Ohri-Gupta
analystAll right, that's great. Thanks a lot.
Emmanuel Babeau
executiveYou're very welcome.
James Bushnell
executiveAppreciate everyone being here today. That brings our call to an end. Should any further questions come up, feel free to reach out to the Investor Relations team. Thanks once more, and enjoy the rest of your day.
Emmanuel Babeau
executiveThank you all. Talk to you soon. Thank you. Bye-bye.
Operator
operatorThanks. That also wraps up today’s session. I appreciate everyone taking part. You’re free to hang up whenever you like.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Philip Morris International Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Philip Morris International Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Philip Morris International Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.